Probiotics Market to Reach $165.1 Billion by 2035, Growing at 8.0% CAGR | Nestlé, Danone, Yakult Honsha Among Key Players

The global probiotics market, valued at USD 70.9 billion in 2024, is on course to reach USD 76.2 billion in 2025 and USD 165.1 billion by 2035, expanding at a compound annual growth rate of 8.0% over the forecast period. Rising consumer investment in preventive health, the mainstreaming of functional foods, and accelerating research into next-generation microbial strains are collectively pushing this market beyond what was possible just five years ago. For investors, brand strategists, and supply chain operators, the next decade in probiotics will be defined by science, not just shelf space.

To explore the complete findings, request a free sample of the report at:
https://www.rootsanalysis.com/reports/probiotics-market/request-sample.html

MARKET OVERVIEW
Probiotics are live, non-pathogenic microorganisms that, when consumed in adequate quantities, confer measurable health benefits on the host. Their primary mechanism involves restoring and maintaining a balanced gut microflora, which supports digestion, immunity, and a growing list of systemic functions including oral, skin, mental, and vaginal health. What was once a niche category in health food stores has become a mainstream consumer staple, sold through supermarkets, pharmacies, specialty retailers, and e-commerce platforms worldwide.

The post-pandemic period accelerated consumer awareness around preventive healthcare, and probiotics sit directly at the intersection of that shift. The category now spans fermented dairy and non-dairy foods, nutritional and specialty supplements, infant formulas, and animal feed, giving it a cross-demographic reach that few health categories can match. Developments in nutrigenomics and precision nutrition are adding another dimension: consumers and clinicians are increasingly looking to probiotics as tools for personalized health management, not just general wellness.

Recent industry activity underscores the commercial seriousness of the space. In August 2024, ZBiotics closed a USD 12 million Series A financing round to support the commercialization of genetically engineered probiotic products. In July 2025, ClostraBio received Generally Recognized as Safe (GRAS) status for its next-generation probiotic strain, Anaerostipes caccae CLB101. The same month, Kaneka Probiotics and AB-BIOTICS announced a probiotic blend specifically designed to slow estrogen reduction in peri- and post-menopausal women. These are not incremental line extensions; they represent a structural shift toward high-value, condition-specific probiotics.

KEY GROWTH DRIVERS
Rising Health Consciousness and Preventive Care Spending Consumers across all income brackets are spending more on products that promise long-term wellness rather than short-term treatment. According to IFIC's 2021 Food and Health Survey, 67% of U.S. adults were familiar with probiotics, with 32% consuming them daily. That baseline awareness, compounded by post-pandemic health prioritization, is translating directly into shelf velocity and repeat purchase rates for both food-format and supplement-format probiotics.

Innovation in Next-Generation and Specialty Strains Research interest in novel microbial strains such as Akkermansia muciniphila and Faecalibacterium prausnitzii is advancing rapidly, with companies investing in genetically modified and highly targeted probiotic formulations. Specialty supplements are forecast to grow at a CAGR of 9.6% through 2035, outpacing the broader market, as developers move beyond generic Lactobacillus formulations toward products with defined clinical endpoints.

Expansion of Pediatric and Infant Applications Research published through the "My Baby Biome" decentralized clinical trial found that approximately 25% of 412 U.S. infants tested lacked detectable Bifidobacterium, creating a clear medical rationale for early-life probiotic intervention. Companies are responding: in September 2024, Persephone Biosciences launched a synbiotic product specifically designed to restore gut microbiome in infants and toddlers. The children and infants segment is forecast to grow faster than the adult segment through 2035.

E-Commerce and Distribution Channel Expansion Online retail is reshaping how consumers discover and repurchase probiotic products. The ability to compare formulations, read clinical summaries, and subscribe to recurring delivery is accelerating trial and loyalty simultaneously. Revenue from online probiotic sales is forecast to grow at one of the highest rates among all distribution channels through the forecast period.

Gut-Brain Axis Research Driving Mental Health Applications A growing body of research connects the gut microbiome to mood regulation, anxiety, and cognitive function. This emerging science is expanding the addressable market for probiotics beyond digestive indications into mental wellness, a category that commands premium pricing and strong consumer engagement.

MARKET SEGMENTATION
By product type, foods and beverages dominate the global probiotics market, accounting for nearly 80% of total revenue in 2025. Within that category, fermented foods hold the largest share at approximately 40%, driven by their deep cultural integration across Asian and European diets and their accessibility as everyday food items rather than supplements. The dairy products sub-segment currently leads within food and beverages, though the non-dairy segment is forecast to grow at a faster rate as plant-based dietary preferences gain ground globally.

The probiotic dietary supplements segment is positioned for strong incremental growth over the next decade. Nutritional supplements capture approximately 60% of supplement-format revenue in 2025, but specialty supplements are the fastest-growing sub-segment at a projected 9.6% CAGR. In terms of target population, adults hold roughly 80% of the overall market share, while the children and infants segment is set to grow at a relatively faster pace. By ingredient type, bacterial strains dominate over yeast and are expected to maintain that position through 2035. The human end-user segment accounts for the majority of market revenue, with animal feed representing a smaller but active adjacent category.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/probiotics-market/request-quote.html

REGIONAL INSIGHTS
Asia-Pacific commands over 47% of the global probiotics market in 2025 and holds the combined distinction of being both the largest and fastest-growing region. Consumer familiarity with fermented foods, a deeply ingrained culture of preventive health, and favorable regulatory environments for novel probiotic registration all contribute to this dominance. Countries including China, Japan, India, and South Korea are active both as consumer markets and as manufacturing hubs, with domestic champions like Yakult Honsha and Morinaga Milk maintaining strong brand equity across the region.

North America is the second-largest market and continues to benefit from high per-capita supplement spending and an active clinical research base that keeps probiotics in the scientific conversation. Europe trails only slightly, with a strong concentration of probiotic ingredient suppliers and research organizations headquartered there, including several of the market's most innovation-active companies. The Middle East and North Africa region is forecast to grow at a relatively high CAGR through 2035, supported by rising health awareness, a young demographic base, and expanding modern retail infrastructure.

COMPETITIVE LANDSCAPE
The global probiotics market features a broad mix of incumbents and innovators. Key players identified in the Roots Analysis report include AB-BIOTICS, ADM, Arla Foods, BioGaia, Danone, General Mills, i-Health, IFF, Kerry, Lallemand, Lifeway Foods, Meiji, Morinaga Milk, Mother Dairy, Nestlé, Novonesis (formed through the merger of Novozymes and Chr. Hansen), Probi, Velbiom, Winclove Probiotics, and Yakult Honsha.

The competitive dynamic spans two distinct tiers. Large FMCG companies like Nestlé and Danone compete on brand trust, distribution scale, and product accessibility; specialist firms like BioGaia and Probi compete on clinical evidence and strain differentiation. The main battleground is shifting toward proprietary strain IP, condition-specific formulations, and the ability to substantiate health claims with credible clinical data. Consolidation is also a visible trend, as illustrated by the Novonesis merger, with larger ingredient suppliers seeking broader strain portfolios to serve both food manufacturers and supplement brands.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/probiotics-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.